NFKB1 and COVID-19: As shown in Fig. 4b, interleukin 6 (IL-6), mitogen-activated protein kinase (MAPK) 1, MAPK8, interleukin-1β (IL-1β), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) p65 subunit (RELA), C-X-C motif chemokine ligand 8 (CXCL-8), C-C motif chemokine ligand 2 (CCL2) and prostaglandin G/H synthase 2 (PTGS2) were the key target proteins for the treatment of COVID-19 with AE.